CEL-SCI Corp.
(NYSE Amex Equities : CVM)

( )
CVM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
ARRYArray BioPharma Inc.
-0.24%46.268.1%$690.49m
AMGNAmgen Inc.
-0.23%177.061.3%$495.97m
CELGCelgene Corporation
-0.72%90.871.3%$431.27m
GILDGilead Sciences, Inc.
-0.03%66.920.9%$401.89m
BIIBBiogen Inc.
-0.91%229.441.3%$372.09m
ILMNIllumina, Inc.
0.20%302.903.5%$354.87m
REGNRegeneron Pharmaceuticals, Inc.
0.35%299.422.6%$268.31m
ALXNAlexion Pharmaceuticals, Inc.
0.48%123.412.0%$197.95m
SRPTSarepta Therapeutics, Inc.
0.49%154.0014.7%$197.25m
VRTXVertex Pharmaceuticals Incorporated
0.56%177.141.9%$181.72m
AAgilent Technologies, Inc.
-0.52%69.591.6%$140.09m
EXASExact Sciences Corporation
1.21%116.3424.1%$137.96m
INCYIncyte Corporation
0.44%80.232.5%$110.35m
BLUEBluebird Bio, Inc.
4.33%139.4514.3%$97.87m
BMRNBioMarin Pharmaceutical Inc.
0.12%82.474.3%$84.42m

Company Profile

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.